Navigation Links
Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
Date:11/7/2012

SAN FRANCISCO, Nov. 7, 2012 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) announced today that the U.S. Food and Drug Administration (FDA) has designated etirinotecan pegol (NKTR-102) as a Fast Track development program for the treatment of patients with locally recurrent or metastatic breast cancer progressing after treatment with an anthracycline, a taxane, and capecitabine (ATC).  Etirinotecan pegol is a unique, targeted topoisomerase I inhibitor designed using Nektar's proprietary polymer conjugate technology. The drug candidate is currently being evaluated in a Phase 3 study in women with metastatic breast cancer.

"We are very pleased that the etirinotecan pegol development program in breast cancer has been granted Fast Track designation and we look forward to continuing to work closely with the FDA on this program," said Robert Medve, MD, Chief Medical Officer of Nektar Therapeutics. "Patients with advanced breast cancer who have progressed following ATC therapies have limited treatment options to manage their disease. As a novel targeted topoisomerase I inhibitor, etirinotecan pegol is a different mechanism of action than currently approved therapies and has the potential to deliver improved efficacy while offering a more tolerable therapy for women with this aggressive disease."

Nektar requested Fast Track designation from the FDA for etirinotecan pegol based upon what is known about its safety and efficacy profile to-date from the nonclinical, Phase 1 and Phase 2 clinical studies, as well as etirinotecan pegol's potential to deliver better efficacy and a more tolerable therapy for patients with locally recurrent or metastatic breast cancer progressing after treatment with ATC.  Etirinotecan pegol, a new topoisomerase I inhibitor, was designed to improve the efficacy of irinotecan by modifying the distribution of the drug candidate
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
3. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
4. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
5. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
6. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
7. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
8. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
9. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
10. Life Technologies Announces Next-Gen Digital PCR Instrument Designed for Widespread Adoption
11. Blue Belt Technologies Announces First United Kingdom-Based NavioPFS Unicondylar Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... --  Vittamed Corporation , a neurodiagnostics medical device company based ... T. (Teo) Forcht Dagi , MD, DmedSc, MPH, MBA, FACS, ... " Teo Forcht Dagi is an experienced ... venture capital," said Remis Bistras , President and CEO ... strategic, and entrepreneurial expertise to our Board." Dr. ...
(Date:8/29/2014)... Research and Markets has announced ... Market 2014-2018" report to their offering. ... that results in demyelination, axonal transection, and neurodegeneration. The ... by the immune system, which targets neurons within the ... disease in which the damage of the myelin sheath ...
(Date:8/29/2014)... -- Pixcelldata, the innovative Irish developer of ... major new deal with Dutch based eX-Path, global providers ... Marius Nap . The announcement was ... Pathology which is taking placing between August 30th and ... where Pixcelldata will demonstrate its innovative solution. ...
Breaking Medicine Technology:Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3Pixcelldata Announces New Deal with Dutch Tele-Pathology Specialists eX-Path Ahead of ECP 2014 2
(Date:8/30/2014)... (PRWEB) August 30, 2014 The Plastic ... in New Jersey and even in the U.S. to ... takes inches off of patients’ waists with deep-tissue heating. ... in small sections, Vanquish is more inclusive to target ... Patients lay comfortably under panels about one inch away ...
(Date:8/30/2014)... RB SEO Services, a well-recognized internet ... small businesses. , RBSEO Services knows this very well ... engine optimization service. So, the company has introduced this ... , On being asked about the service, a ... cost SEO service because many small businesses expressed their ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 The ... the planet has been one of the main ... to create a positive impact around the world. ... staffed with top trained executives and trainers deliver ... people worldwide. Vital statistics demonstrate that significant ...
(Date:8/30/2014)... Acne is a common problem millions of American cope with ... a daily nuisance, for some, it can have a crippling impact ... lead to dramatic mood swings and depression. , Those struggling ... their skin. In some cases, that can make the problem even ... those on a quest for clearer skin can now view ...
(Date:8/30/2014)... Seniors Guide, the comprehensive guide to all ... Alzheimer’s Disease, Dementia, and Memory Loss . , Country ... being diagnosed with the Alzheimer’s, inspired Seniors Guide writers to ... The movie, out on October 14, 2014, shows a ... of the disease – which inspires a final tour from ...
Breaking Medicine News(10 mins):Health News:NJ Top Docs Presents, The Plastic Surgery Group 2Health News:RBSEO Services Introduces Low Cost SEO Service for Small Businesses 2Health News:Cradle of Aviation Museum Opens Its Doors to Long Island Scientologists 2Health News:Acne Treatment Reviews Added to Popular Treatment Website 2Health News:Alzheimer’s Disease and Dementia Focus on Retirement Website SeniorsGuideOnline.com 2
... Biosciences LLC, a Boston-based company conceived in partnership ... today that Johnson & Johnson has joined the ... will have the opportunity to invest in the ... to fundamentally transform drug discovery and development and ...
... Limited (Nasdaq: WCRX ) announced today that ... close on Tuesday, January 27, 2009. In addition to ... Executive Officer and Paul Herendeen, Executive Vice President and ... audio webcast to discuss the 2009 Financial Guidance for ...
... Keystone Symposium - Obesity: Novel Aspects of the Regulation ... Genetics, Inc. (NYSE Alternext US: ILI) announced today that ... role genetics play in an individual,s ability to lose ... during tomorrow,s Keystone Symposium titled, "Obesity: Novel Aspects of ...
... Blood Bank is honored to announce that it has ... of Cellular Therapy ("FACT"). CORD:USE is a leading ... processing, storage and distribution of donated cord blood. ... more than 14,000 patients with over 70 life-threatening diseases ...
... DIEGO, Jan. 22 Aero Financial, Inc, a strategic ... that the company has been retained as a strategic ... distributor of natural health information and nutrition products.Pursuant to ... Finest(TM) in several facets of the company,s growth plans, ...
... for 11:00 a.m. ET POWAY, Calif., Jan. 22 ... provider of diagnostic imaging products and services that improve ... before the market opens on Thursday, February 5, 2009, ... December 31, 2008. A conference call is scheduled for ...
Cached Medicine News:Health News:Enlight Biosciences Expands to direct up to $52 Million to Transformational Enabling Technologies 2Health News:Enlight Biosciences Expands to direct up to $52 Million to Transformational Enabling Technologies 3Health News:Interleukin Genetics to Present Data Highlighting Link Between Inflammatory Gene Variations and Less Effective Weightloss 2Health News:Interleukin Genetics to Present Data Highlighting Link Between Inflammatory Gene Variations and Less Effective Weightloss 3Health News:CORD:USE Cord Blood Bank Receives Prestigious Accreditation from the Foundation for the Accreditation of Cellular Therapy 2Health News:Aero Financial Retained as Strategic Consultant by Only Natures Finest(TM) 2Health News:Digirad Corporation to Release Fourth Quarter and Year-End Financial Results on February 5, 2009 2
... Ultralight Jarrod Goggles have set the ... Nonslip soft silicone saddle nose bridge. ... better and lasts longer. Adjustable elastic ... without breakable plastic strap clips. 0.75 ...
QualCraft™ Radiation-Reducing Eyewear is 50% lighter than other protective eyewear. Manufactured for the ultimate combination of comfort, function, and protection....
QualCraft™ Radiation Protection Eyewear providex maximum comfort and eye protection! Lenses made of 0.75 mm leaded glass. Side shields of 0.30 mm leaded acrylic help seal out scatter radiation ...
Portable shields for your safety and convenience....
Medicine Products: